Aspirin for Secondary Prevention of Cardiovascular Events

Information provided by Bayer

Patients who are on aspirin regimens may be confused about the recent updates regarding the use of aspirin to help prevent cardiovascular events, like heart attack and ischemic stroke.

The new guidelines issued by the American College of Cardiology and American Heart Association in March 2019 apply to the use of aspirin to help prevent a first heart attack or ischemic stroke, also known as primary prevention. These guidelines are still supportive of the use of aspirin to help prevent a first event for certain individuals based on their personal health risk and doctor’s recommendation.

Some people take aspirin because they’ve already had a heart attack or ischemic stroke, also known as secondary prevention. In the United States, aspirin is indicated to help prevent a recurrent heart attack or ischemic stroke under a doctor’s direction.


The new guidelines do not change the importance of aspirin for these patients. For them, aspirin could be a life-saving preventative treatment. The guidelines also do not change the role of aspirin during a suspected heart attack as directed by a doctor.

In fact, studies have found that for patients who have had a heart attack or ischemic stroke an aspirin regimen can help reduce risk by:

  • 31 percent for another heart attack
  • 22 percent for another ischemic stroke  


It can also help reduce the risk of death by 23 percent if taken during a suspected heart attack and for 30 days thereafter.

It’s important that patients do not start, stop or change an aspirin regimen without first consulting their healthcare provider, especially those who have already had a heart attack or ischemic stroke. For them, stopping an aspirin regimen could increase their risk by:

  • 63 percent for another heart attack
  • 40 percent for another ischemic stroke

Below you can download a handy fact sheet about how aspirin can help prevent another heart attack or ischemic stroke, which may be useful during conversations with your patients.

For more information, you can also visit bayeraspirinhcp.com(www.bayeraspirinhcp.com).

References:

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019.

Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised clinical trials. The Lancet. 2009; 373:1849-1860.

ISIS-2 Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. The Lancet. 1988; 332: 8607; 349-360.

Garcia Rodriguez LA, Cea-Soriano L, Martin-Merino E, et all. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011; 343:d4094.

Garcia Rodriguez LA, Cea-SorianoL, Martin-Merino E, et all. Increased risk of stroke after discontinuation of acetylsalicylic acid. Neurology. 2011; 343:d4094.

Free Test Summary provided by Quest DiagnosticsFree Test Summary provided by Quest Diagnostics

Disclaimer

The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.